Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nanologica AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:NICA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.25 Med: -0.77 Max: 2.74
Current: 2.74
During the past 12 years, the highest Debt-to-EBITDA Ratio of Nanologica AB was 2.74. The lowest was -1.25. And the median was -0.77.
OSTO:NICA's Debt-to-EBITDA is ranked worse than 63.92% of 316
companies
in the Biotechnology industry
Industry Median: 1.255
vs OSTO:NICA: 2.74
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nanologica AB Debt-to-EBITDA Related Terms
Nanologica AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Nanologica AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nanologica AB (OSTO:NICA) has a Debt-to-EBITDA of 0.41 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanologica AB. According to the industry distribution chart, Nanologica AB ranks #202 out of 316 companies in the Biotechnology industry, placing it in the top 63.9%.
Is Nanologica AB's Debt-to-EBITDA too high?
Nanologica AB's current Debt-to-EBITDA is 0.41. The Biotechnology industry median Debt-to-EBITDA is 1.26. Nanologica AB's value of 0.41 is 67.3% below this industry median. Based on the distribution chart, Nanologica AB ranks #202 out of 316 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #202 out of 316 companies for Debt-to-EBITDA. This places Nanologica AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. Nanologica AB's value of 0.41 is 67.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current Debt-to-EBITDA of 0.41 is 67.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanologica AB. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current Debt-to-EBITDA is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.33, compared to a current price of kr0.49 — trading 88.7% below its estimated fair value. The current Debt-to-EBITDA is 0.41 and 67.3% below the Biotechnology industry median of 1.26. Nanologica AB's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Debt-to-EBITDA is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.49 is trading 88.7% below its estimated GF Value™ of kr4.33.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Debt-to-EBITDA: 0.41
GF Value™: kr4.33 vs. price of kr0.49 (88.7% below fair value)
Industry Position: 67.3% below the Biotechnology median (#202 of 316)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score
Get the complete analysis for OSTO:NICA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
